芪苈强心胶囊治疗扩张型心肌病伴慢性心衰患者的临床观察

Clinical Observation on Qili Qiangxin Capsules in the Treatment of Patients with Dilated Cardiomyopathy Complicated with Chronic Heart Failure

目的:探讨芪苈强心胶囊对扩张型心肌病(DCM)伴慢性心衰竭患者的治疗效果。方法:选取2020年3月-2022年3月于宜春市第二人民医院接受治疗的DCM伴慢性心衰竭88例患者为研究对象,根据系统随机化法将其分成对照组与观察组,每组44例。对照组给予临床较为常见的西药治疗,观察组则在对照组基础上给予芪苈强心胶囊治疗。比较治疗前及治疗3个月后,两组患者心功能指标[左室射血分数(LVEF)、左室收缩末期内径(LVESD)]、血管内皮功能指标[血清内皮素-1(ET-1)、血管性假血友病因子(vWF)]、左心室重构标志物[血清可溶物ST2(sST2)、半乳凝集素(Gal-3)]、血脂指标[甘油三酯(TG)、低密度脂蛋白(LDL)]水平。结果:治疗后,两组患者LVESD、ET-1、vWF、sST2、Gal-3、TG、LDL均较治疗前下降,LVEF均上升(P<0.05);治疗后观察组的LVESD、ET-1、vWF、sST2、Gal-3、TG、LDL水平明显均低于对照组,LVEF水平高于对照组(P<0.05)。结论:芪苈强心胶囊治疗扩张型心肌病伴慢性心衰竭疗效突出,可改善患者心功能、血管内皮功能及血脂代谢,并抑制左心室重构,对其预后康复有利。

Objective:To investigate the therapeutic effects of Qili Qiangxin Capsules on patients with dilated cardiomyopathy(DCM)and chronic heart failure.Method:A total of 88 patients with DCM and chronic heart failure who were treated in Yichun Second People's Hospital between March 2020 and March 2022 were selected as the research subjects,and they were divided into the observation group and the control group with 44 cases in each group according to the systematic randomization method.The control group was treated with conventional western medicine while the observation group was given Qili Qiangxin Capsules on the basis of control group.The cardiac function indicators[left ventricular ejection fraction(LVEF),left ventricular end-systolic diameter(LVESD)],vascular endothelial function indicators[serum endothelin-1(ET-1),von Willebrand factor(vWF)],left ventricular remodeling markers[serum soluble ST2(sST2),galectin(Gal-3)]and blood lipid indicators[triglyceride(TG),low-density lipoprotein(LDL)]were compared between the two groups of patients before treatment after 3 months of treatment.Result:After treatment,the levels of LVESD,ET-1,vWF,sST2,Gal-3,TG and LDL in the two groups were significantly decreased compared with those before treatment while the level of LVEF were significantly increased(P<0.05).After treatment,the levels of LVESD,ET-1,vWF,sST2,Gal-3,TG and LDL in the observation group were significantly lower than those in the control group,while the level of LVEF was higher than that in the control group(P<0.05).Conclusion:Qili Qiangxin Capsules has a prominent efficacy in treating dilated cardiomyopathy with chronic heart failure,and can improve the cardiac function,vascular endothelial function and blood lipid metabolism,and inhibit the left ventricular remodeling,and it is beneficial to prognosis and recovery.